Delivery Order SPE2DB24D1205-SPE2DB25FDACU
Award Date 9/4/25
Potential Completion Date 9/5/25
Potential Value $9.7K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $2,527.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 4, 2025, with completion scheduled for September 5, 2025. HEPLISAV-B is a recombinant zoster vaccine indicated for prevention of herpes zoster in adults 50 years of age and older. This non-set-aside award was competitively procured and will be performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at $5,303.54 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with an ultimate completion date of July 21, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. HEPLISAV-B is a recombinant zoster vaccine indicated for the prevention of herpes zoster in adults aged 50 years and older, representing part of the federal government's medical supply requirements for military...
- The Defense Logistics Agency awarded a delivery order valued at $8,424.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 2, 2025, with completion expected by September 3, 2025. This delivery order represents a firm fixed-price contract with no set-aside designation, awarded through competitive procurement. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for...
- The Defense Logistics Agency awarded a delivery order valued at $2,106.20 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults aged 18 and older, and this...
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.15 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 ml syringes on August 7, 2025, with completion expected by August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for use in adult populations, representing part...
- The Defense Logistics Agency awarded a delivery order valued at $1,263.72 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed price delivery order represents a non-competitive set-aside award and is being performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B virus infection in adults 18...
- The Defense Logistics Agency awarded a delivery order valued at $8,424.80 to AmerisourceBergen Drug Corp on August 4, 2025, for HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price delivery order with an ultimate completion date of August 5, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competitively awarded. HEPLISAV-B is a recombinant hepatitis B vaccine commonly procured by...
- The Defense Logistics Agency awarded a delivery order valued at $114,722.94 to AmerisourceBergen Drug Corp for HEPLISAV-B vaccine (20 mcg/0.5 ml syringes). This competitively awarded, firm fixed-price delivery order was issued on September 3, 2025, with an ultimate completion date of September 4, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,637.55 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine approved for use in adults,...